

CURRICULUM VITAE

TERRENCE L. SCHWINGHAMMER

Office Address: Department of Clinical Pharmacy
1124 Health Sciences North
PO Box 9520
Morgantown, West Virginia 26506

Office Phone: (304) 293-2573
Cell Phone: (412) 398-5452
Fax: (304) 293-7672
Internet: tschwinghammer@hsc.wvu.edu

Home Address: 1125 Riggs Court
Washington, Pennsylvania 15301
(412) 398-5452

Date of Birth: October 18, 1950

EDUCATION

1975-1977	Purdue University	Doctor of Pharmacy
1976-1977	Indiana University Hospitals	Hospital/Clinical Residency
1968-1973	Purdue University	Bachelor of Science, Pharmacy

APPOINTMENTS AND POSITIONS

ACADEMIC:

2005-Present	Professor and Chair, Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV.
2001-2005	Professor of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA.
1983-2001	Associate Professor, School of Pharmacy, University of Pittsburgh.
1992	Interim Director, Doctor of Pharmacy Program, University of Pittsburgh.
1977-1983	Assistant Professor of Pharmacy Practice, University of Pittsburgh School of Pharmacy.
1976-1977	Hospital/Clinical Resident, Indiana University Hospitals, Indianapolis, IN.
1975-1976	Teaching Assistant, Clinical Pharmacy Department, Purdue University School of Pharmacy and Pharmacal Sciences, West Lafayette, IN.
1973-1975	Clinical Instructor, Purdue University Externship, Memorial Hospital, Jasper, IN.

NON-ACADEMIC:

1996-2005	Volunteer Pharmacist, Program for Pharmaceutical Care for Underserved Populations, Pittsburgh, PA.
1996-2005	Ambulatory Care Pharmacist, University of Pittsburgh Medical Center.
1992-1996	Pharmacy Specialist, Bone Marrow Transplant Unit, Pittsburgh Cancer Institute, Montefiore University Hospital, Pittsburgh, PA.
1977-1991	Clinical Pharmacist, Adult Medicine, Montefiore Hospital, Pittsburgh, PA.
1987-1989	Preceptor, Pennsylvania State Board of Pharmacy Internship Program.
1978-1989	Staff pharmacist (part-time), Pitt Student Health Service Pharmacy, Pittsburgh, PA.
1985-1988	Staff pharmacist (part-time), Montefiore Hospital, Pittsburgh, PA.

APPOINTMENTS AND POSITIONS (continued)

NON-ACADEMIC: (continued)

1973–1975 Staff pharmacist, Memorial Hospital, Jasper, IN.
1974–1975 Retail pharmacist (part–time), Kesling Rexall Pharmacy, Huntingburg, IN.
1973–1974 Staff pharmacist (part–time), Huntingburg Clinic, Huntingburg, IN.
1973 Pharmacy extern, Memorial Hospital, Jasper, IN.
1969 Pharmacy intern, Memorial Hospital, Jasper, IN.

PHARMACY LICENSURE AND CERTIFICATION

1973–Present	Registered Pharmacist (#26012963)	State of Indiana
1978–Present	Registered Pharmacist (#RP-029877-L)	Commonwealth of Pennsylvania
1991–Present	Board Certified Pharmacotherapy Specialist (#291194)	Board of Pharmaceutical Specialties Recertified for the period of 2005–2012

HONORS AND AWARDS

1972 Member, *Rho Chi Pharmaceutical Honor Society*.
1983 Awarded permanent tenure at the University of Pittsburgh School of Pharmacy.
1993 *Fellow*, American College of Clinical Pharmacy.
1994 *Hygeia Teacher of the Year*, the 1994 graduating pharmacy class, Univ. Pittsburgh.
1995 *Faculty Member of the Year for 1994*, Academy of Students of Pharmacy, Pittsburgh.
1996 *Hygeia Teacher of the Year*, the 1996 graduating pharmacy class, Univ. Pittsburgh.
1998 *Pharmacy Leadership Award*, Bristol-Myers Squibb.
1998 *Letter of Commendation*, the Office of the Vice Chancellor for Student Affairs, Univ. Pittsburgh, recognizing positive interaction with students.
1998–2000 *Honors Convocation Recognition*, University of Pittsburgh, for achievements that characterize the quality of academic life at the University.
1999 *Faculty Member of the Year for 1998*, Academy of Students of Pharmacy, Pittsburgh.
1999 *Distinguished Achievement Award in Clinical/Pharmacotherapeutic Practice*, APhA Academy of Pharmacy Practice and Management.
1999 *Fellow*, the American Society of Health-System Pharmacists.
2000 *Hugh C. Muldoon Memorial Lecture Award*, the Alpha Beta Chapter of the Rho Chi Pharmaceutical Honor Society, Duquesne University.
2000 Member, *Phi Lambda Sigma National Pharmacy Leadership Society*.
2000 *Stanford I. Cohen Teacher of the Year Award*, by the 2000 graduating pharmacy class, the first entry-level doctor of pharmacy degree class.
2001 *Pharmacist of the Year*, Pennsylvania Society of Health-System Pharmacists.
2004, 2008 *Visiting Professor*, Misr International University School of Pharmacy, Cairo, Egypt.
2004 *Distinguished Alumnus*, Purdue University School of Pharmacy.
2005 *Certificate of Appreciation* for lectures and consultations to hospital pharmacists, The Japanese Society of Hospital Pharmacists, Kagoshima, Japan.
2005 *Community Service Award*, the Pennsylvania Society of Health-System Pharmacists.
2006 *Distinguished Practitioner*, the National Academies of Practice, Academy of Pharmacy.
2007 *Sister Gonzales Duffy Award*, Pennsylvania Society of Health-System Pharmacists.
2007–2008 *Academic Leadership Fellows Program*, American Association of Colleges of Pharmacy.
2008 Editor-in-Chief of AccessPharmacy.com, which received the 2008 Award for *Best Electronic Publication or Product for Excellence in Scholarly Publishing* from the Association of American Publishers.

HONORS AND AWARDS (continued)

2008 Co-recipient of a 2008 *Medical Book Award* from the American Medical Writers Association as co-editor of *Pharmacotherapy Principles & Practice, 1st edition*.

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1970–Present Kappa Psi Pharmaceutical Fraternity
1972–Present Rho Chi Pharmaceutical Honor Society
1973–Present American Pharmacists Association
1977–Present American Society of Health–System Pharmacists
1977–2006 Western Pennsylvania Society of Health–System Pharmacists
1979–2006 Pennsylvania Society of Health–System Pharmacists
1979–Present American Association of Colleges of Pharmacy
1987–2005 University of Pittsburgh Cancer Institute (elected)
1988–Present American College of Clinical Pharmacy (elected)
1999–Present American Institute of the History of Pharmacy
2000–Present Phi Lambda Sigma National Pharmacy Leadership Society
2006–Present West Virginia Pharmacists Association

TEACHING RESPONSIBILITIES

WEST VIRGINIA UNIVERSITY, 2005–Present

Doctor of Pharmacy Courses (Team Taught)

2006–Present	PHAR 703	Introductory Pharmacy Practice Experience 1 (Facilitator)
2006–Present	PHAR 712	Pharmaceutical Care Lab 2 (Facilitator)
2006–Present	PHAR 724	Pharmaceutical Care Lab 4 (Facilitator)
2006–Present	PHAR 725	Pathophysiology & Therapeutics 2 (Lecturer)
2006–2007	PHAR 735	Pharmaceutical Care Lab 5 (Course Co-Coordinator)
2006–Present	PHAR 736	Pharmaceutical Care Lab 6 (Facilitator)
2006–Present	PHAR 739	Therapeutic Patient Monitoring (Lecturer)
2007	PHAR 710	Introductory Pharmacy Practice Experience 2 (Facilitator)
2007–Present	PHAR 715	Pathophysiology & Therapeutics 1 (Lecturer, Facilitator)
2007	PHAR 723	Pharmaceutical Care Lab 3 (Facilitator)
2007–Present	PHAR 742	Introductory Pharmacy Practice Experience 5 (Facilitator)
2008–Present	PHAR 746	Introductory Pharmacy Practice Experience 6 (Facilitator)

UNIVERSITY OF PITTSBURGH, 1977–2005

Graduate Committee Member, School of Pharmacy

Christine L. Derry, PhD	1991
Reginald F. Frye, PharmD, PhD	1995

Doctor of Pharmacy Advisor

William C. Zamboni, BS, PharmD	1994	Meggan Landman, PharmD	2003
Denise Bojarski, BS, PharmD	1997	Nicole Lykowski, PharmD	2004
Nicole Ansani, BS, PharmD	1998	Lucy Chiao, PharmD	2004

Doctor of Pharmacy Advisor (continued)

Madeline Betancourt, BS, PharmD	1999	Jennifer Saline, PharmD	2005
Diane McIntyre, PharmD	2000	Theresa Mehall, PharmD	2005
Karen Epstein, PharmD	2001	Christine Huber, PharmD	2006
Timothy Muccino, PharmD	2002	David Julian, PharmD	2007

Doctor of Pharmacy and Graduate Courses (Team Taught)

1985–1992	Pharmacy 3012–3015	Advanced Ph.D. Clerkships I–IV (Course Director, 1985–1992)
1985–1990	Pharmacy 3016–3017	Advanced Therapeutics I and II (Course Director, 1986)
1992–1993	Pharmacy 3403	Doctor of Pharmacy Seminar
1993–1998	Pharmacy 3019	Experimental Design for Clinical Research
1994–1999	Pharmacy 3409–17	Post-B.S. Doctor of Pharmacy Clerkships
1996–1998	Pharmacy 3428	Gastroenterology Module (Course Director)
1998–2001	Pharmacy 5316*	Pulmonology/Rheumatology (Guest Lecturer)
1997–2005	Pharmacy 5210*	Profession of Pharmacy 3 (Course Coordinator)
1998–2005	Pharmacy 5211*	Profession of Pharmacy 4 (Course Coordinator)
1998–2005	Pharmacy 5111*	Profession of Pharmacy 2 (Practicum Participant)
1998–2005	Pharmacy 5212–13*	Experiential Learning 3 and 4 (Faculty Advisor)
1998–2005	Pharmacy 5217*	Nephrology (Group Discussion Leader)
1999–2005	Pharmacy 5401–07*	Advanced Pharmacy Practice Experiences

* Indicates courses in the four-year Doctor of Pharmacy curriculum implemented in the Fall Term, 1996.

Baccalaureate in Pharmacy Courses (Team Taught)

1977–1999	Pharmacy 1500	Clinical Pharmacy Clerkship (Preceptor)
1979, 1991, 1994	Pharmacy 1790	Undergraduate Research Elective
1980	Pharmacy 1490	Nonprescription Products
1981–1998	Pharmacy 1420	Disease Management I
1981–1986	Pharmacy 1400	Introduction to Clinical Pharmacy
1986–1989	Pharmacy 1400	Drug Information and Literature Evaluation
1993–1998	Pharmacy 1430	Disease Management II
1994–1995	Pharmacy 1330	Pharmacognosy and Natural Products (Guest Lecturer)
1994–1997	Pharmacy 1700	Advanced Pharmacy Practice: Immunology Module

School of Medicine Courses (Team Taught)

2003–2006	ILS 5710	Selective in Clinical Pharmacology (Guest Lecturer)
-----------	----------	---

SERVICE

COMMITTEES:

PROFESSIONAL ORGANIZATIONS

American Society of Health–System Pharmacists

- 1991–1992 Selection Panel for Research and Education Foundation *Literature Awards Program*.
- 1991–1998 Selection Panel for Research and Education Foundation *Demonstration Projects Grants and New Pharmacy Practice Researcher Grants Programs*.
- 1992–1995 Selection Panel for Research and Education Foundation *Research Awards Program*.
- 1993–2003 Selection Panel for Research and Education Foundation *Drug Therapy Research Award*.
- 1993 Educational Programming Associate, Midyear Clinical Meeting, Atlanta, GA, Dec. 1993.
- 1997–2000 House of Delegates, representing the Pennsylvania Society of Health–System Pharmacists.
- 1998–1999 Member, ASHP State Chapter Grants Selection Panel.
- 2000 Author of the sample case for the 2000 ASHP Clinical Skills Competition Coordinator Handbook.
- 2000–2007 Meeting Program Associate for ASHP Midyear Clinical Meetings.
- 2001–2002 Member, Council on Educational Affairs.
- 2001–2002 Selection Panel for Research and Education Foundation *Basic Science – Applied Therapeutics Research Grant Awards*.
- 2001–2002 Member, Design Team for the Learning Community on Management and Leadership held at the 2002 Summer Meeting.
- 2001–2005 Faculty Liaison for the University of Pittsburgh School of Pharmacy.
- 2002–2003 Member, Council on Educational Affairs.
- 2002–2003 Member, Design Team for a Learning Community for the 2003 Summer Meeting.
- 2002 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Atlanta, GA, December 7–8, 2002.
- 2002–Present Mentor in the Virtual Mentoring Program launched by ASHP during the ASHP Midyear Clinical Meeting in Atlanta, GA, December, 2002.
- 2003–2004 Member, Council on Educational Affairs.
- 2003 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in New Orleans, LA, December 6–7, 2003.
- 2004 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Orlando, FL, December 4–5, 2004.
- 2005 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Las Vegas, NV, December 3–4, 2005.
- 2006 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Orlando, FL, December 2–3, 2006.
- 2007 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Las Vegas, NV, December 1–2, 2007.
- 2008 Member, Panel of Judges for the ASHP National Clinical Skills Competition at the Midyear Clinical Meeting in Orlando, FL, December 6–7, 2007.

Pennsylvania Society of Health–System Pharmacists

- 1987 Program Committee, Midyear Conference VIII, Pittsburgh, PA; March 12–13, 1987. Moderator, Kinetics Workshop.
- 1987–1988 Chair, Program Committee, Twentieth Annual Assembly, Philadelphia, PA; October 5–7, 1988. Moderator, General Session I. Moderator, Student Forum. Moderator, Therapeutics Workshop.
- 1990–1991 Program Committee, Midyear Conference XII, Pittsburgh, PA; March 21–22, 1991. Discussion Leader, Breakfast Roundtable Session on Adult Medicine. Discussion Leader, Roundtable Session on Graduate Programs. Moderator, Breakout Workshop on Basic Monitoring Skills.
- 1992 Steering Committee for the invitational consensus conference *Directions for Pharmaceutical Care in Pennsylvania*, Harrisburg, PA; October 29–30, 1992.
- 1993–1996 Awards and Nominations Committee.
- 1993–1996 Board of Directors, Member–at–Large.
- 1994–1996 Board Liaison to the Education Task Force.
- 1995–1997 Pharmaceutical Care Task Force, the steering committee for *the Second Statewide Pharmaceutical Care Conference*, Harrisburg, PA, November 15–16, 1996.
- 1996 Board Liaison to the Professional Practice Council.
- 1996–1999 Presidential Officer and Member of the Executive Committee.
- 1996–1997 President–Elect.
- 1996–1997 Chair, Awards and Nominations Committee.
- 1996–1999 Finance Committee.
- 1997 Search Committee for the Executive Vice President.
- 1997–1999 Pennsylvania Pharmacy Liaison Group.
- 1997–1998 President and Chair of the Board of Directors.
- 1998–1999 Immediate Past President.
- Board Liaison for the Technician Subcommittee.
- Board Liaison to the Legislative Committee.
- 1999–2001 Legislative Committee.
- 1999–2003 Finance Committee.
- 1999–2005 Educational Advisory Council.
- 2000–2001 *Ad Hoc* Committee to Evaluate Meeting Structure, Format, and Duration.
- 2000–2005 Student Section Task Force.
- 2001 Council on Legislative Affairs.

Western Pennsylvania Society of Health-system Pharmacists (WPSHP)

- 2000–2001 Member, Board of Directors.
- 2000–2001 Chair, Legislative Committee.

American Association of Colleges of Pharmacy

- 1992–1994 House of Delegates, representing the University of Pittsburgh.
- 1994–1996 Pharmacy Practice section Task Force to Address Experiential Experiences for Entry-Level Pharm.D Education.
- 1995–1999 Annual Review Panel for the New Investigator Proposal Grants Program.
- 1995–1996 Alternate Member, House of Delegates, representing the University of Pittsburgh.
- 1996–1998 Secretary, Section of Teachers of Pharmacy Practice (2-year elected term of office).
Ex officio member, Section Archives Committee.
Ex officio member, Section Program Committee.

American Association of Colleges of Pharmacy (continued)

- 1999–2002 Section of Teachers of Pharmacy Practice:
Chair-elect, 1999–2000
Chair, 2000–2001
Immediate Past-Chair, 2001–2002
- 1999–2000 Chair, Program Committee, Section of Teachers of Pharmacy Practice.
- 1999–2000 Chair, Pharmacy Practice Review Panel for the New Investigators Program.
- 1999–2001 Member, Academic Sections Coordinating Committee.
- 2000–2001 Chair, Pharmacy Practice Review Panel for the New Investigators Program.
- 2001–2002 Member, Pharmacy Practice Review Panel for the New Investigators Program.
- 2001–2002 Chair, Nominations Committee, Section of Teachers of Pharmacy Practice.
- 2002–2004 Chair, Strategic Planning Commission, Section of Teachers of Pharmacy Practice.
- 2003–2006 Council of Faculties:
Administrative Board Member, 2003–2006
Chair-elect, 2003–2004
Chair, 2004–2005
Immediate Past-Chair, 2005–2006
Chair of the COF Nominating Committee, 2005–2006
- 2003–2006 Member, AACP Board of Directors.
2003–2004 Member, Planning Group for the 2004 Teachers Seminar.
2003–2004 Strategic Planning Subcommittee of the Board of Directors.
2004–2006 *ad hoc* Accreditation Standards and Guidelines Review Committee.
2005 Nominating Subcommittee for AACP Appointment to ACPE.
2005–2006 Strategic Planning Subcommittee of the Board of Directors.
- 2004 Member, Credentials Committee for the 2004 Annual Meeting, Salt Lake, Utah.
- 2005 Member, Credentials Committee for the 2005 Annual Meeting, Cincinnati, Ohio.
- 2005–2006 Member, CAPE Educational Outcomes and Objectives Supplements Task Force.
- 2007 Discussion Leader, Department Chairs Roundtable Session, 2007 Annual Meeting.
- 2007 Chair, Pharmacy Practice Review Panel 3 for the New Investigator Program.
- 2007–2008 Member, Robert K. Chalmers Distinguished Pharmacy Educator Award Committee.
- 2007–2008 Member, AACP/ASHP Joint Capacity for Experiential Education Survey Project.

American College of Clinical Pharmacy

- 1990–1991 Nominations Committee, Three Rivers Chapter.
- 1990–1992 Credentials Committee (two consecutive terms).
- 1991–1992 Program Committee, Winter Practice and Research Forum, Phoenix, AZ, February 9–12, 1992. Moderator for the symposium *New Drugs 1991*.
- 1992–1993 Program Committee, Winter Practice and Research Forum, Fort Lauderdale, FL, February 7–10, 1993. Moderator for symposium *New Drugs '92*.
- 1993–1996 Immunology/Transplantation Practice and Research Network.
- 2005–2007 Research Institute Grants and Fellowships Selection Committee.
Member, Frontiers Career Development Research Awards Panel.
Member, Investigator Development Research Awards Panel.

Board of Pharmaceutical Specialties

- 2005–2010 Board Member and Liaison to the American Association of Colleges of Pharmacy (served two consecutive three-year terms).
- 2005–2008 Member, Finance Committee; Chair 2007–2008.
- 2007–2009 Member, Executive Committee.
- 2007–2008 Vice Chair, Board of Pharmaceutical Specialties.
- 2008–2009 Chair, Board of Pharmaceutical Specialties.

WEST VIRGINIA UNIVERSITY SCHOOL OF PHARMACY COMMITTEES

- 2005–Present Executive Committee.
- 2005–2006 Search Committee for the Deanship.
- 2005–2006 Strategic Research Planning Committee.
- 2005–2007 Assessment for Excellence Committee.
- 2005–Present Promotion and Tenure Guidelines Review Committee (co-chair, 2008–09)
- 2006–2007 Search Committee for the School Expert Business Officer.
- 2006–2007 Search Committee for the Associate Dean for Research and Graduate Programs.
- 2006–2008 Renovation Team.
- 2006–Present Experiential Education Committee (*ex officio*).
- 2006–Present Wigner Institute Design Team.
- 2007–Present Residency Committee (*ex officio*).
- 2007–2008 *Ad Hoc* Technology Committee.
- 2008–2010 ACPE Self-Study Steering Committee; co-chair, Faculty & Staff Subcommittee

WEST VIRGINIA UNIVERSITY HOSPITALS AND HEALTH SCIENCES CENTER COMMITTEES

- 2007–Present Quality Patient Safety Committee, West Virginia University Hospitals.
- 2007–Present Subject Matter Expert (SME) Committee, WVU Hospitals Epic/Merlin project.
- 2007–Present Simulation Center Planning Committee, WVU Health Sciences Center.

UNIVERSITY OF PITTSBURGH SCHOOL OF PHARMACY COMMITTEES

- 1977–2004 Awards Committee.
- 1980–2001 Academic Performance Committee.
- 1983–1984 Self-Study Committee for ACPE Accreditation.
- 1984–2005 Promotion and tenure committees.
- 1985–1988 Steering Committee, Clinical Pharmaceutical Scientist Program.
- 1986–1989 Committee on Graduate Studies.
- 1987 Search Committee for the Deanship.
- 1989–1990 Chair, Doctor of Pharmacy Program Development Committee.
- 1989–1991 Residency and Fellowship Committee.
- 1989–1993 Executive Committee; Department of Pharmacy and Therapeutics.
- 1989–1995 Delegate, United States Pharmacopeial Convention.
- 1990–1991 Post-Graduate Studies Committee.
- 1990–1991 Search Committee for Drug Information Specialists.
- 1992 Interim Planning and Budgeting Committee.
- 1992–1993 Academic Integrity Committee.
- 1992–1995 Advisory Committee, University of Pittsburgh Pharmacy Associates (UPPA).
- 1992–1993 Continuing Education Committee.

UNIVERSITY OF PITTSBURGH SCHOOL OF PHARMACY COMMITTEES (continued)

1992–1993	Pharmaceutical Care Task Force for Curriculum Reconstruction.
1992–1997	Doctor of Pharmacy Applicant Selection Committee.
1993–1994	Co-chair, Curriculum Team I (planning for years 1 & 2 of entry-level program.)
1994	Search committee for Experiential Education Coordinator.
1994–1995	Co-Chair, Faculty and Staff Internal Campaign.
1994–1996	Excellence in Teaching Award Committee.
1994–2001	Chair, Curriculum Committee.
1994–1999	Post-Baccalaureate Pharm.D. Program Steering Committee (<i>ex officio</i>).
1996	<i>Ad hoc</i> planning committee for research seminar series.
1996–1997	Self-Study Committee for ACPE Accreditation.
1996–1997	<i>Ad hoc</i> committee to revise School guidelines for faculty appointment, promotion, tenure.
1998	Chair, Search Committee for a faculty member in the social and administrative sciences.
1999–2005	Search Committees for a faculty member in oncology.
2000	Chair, Task Force for Evaluating Experiential Learning Outcomes.
2000–2001	Search Committee for a clinical faculty member in Nutrition Support.
2001–2005	Code of Conduct Committee.
2001–2002	Self-Study Committee for ACPE Accreditation.
2001–2004	Strategic Planning Committee.
2001–2003	Working Group on Educating the Next Generation of Practitioners and Scientists.
2002–2003	Search Committee for a faculty member in internal medicine.
2002–2003	Search Committee for a faculty member in drug information.
2002–2003	Working Group on Student Recruitment.
2003–2005	Doctor of Pharmacy Program Council.
2003–2005	Chair, Faculty and Student Awards Committee.
2003–2004	Search Committee for the Deanship.

UNIVERSITY OF PITTSBURGH HOSPITAL AND HEALTH-SYSTEM COMMITTEES

1983–1991	Pharmacy and Therapeutics Committee; Montefiore Hospital.
1990–1991	Subcommittee on Adverse Drug Reactions.
1989–1991	Subcommittee on Drug Use Evaluation.
1983–1991	Subcommittee on I.V. Medications.
1985–1988	Medical Audit Committee; Montefiore Hospital.
1989–1991	Ad Hoc Committee on Investigational Agents; Presbyterian–University Hospital.
1990	Chair, Decentralized Satellite Task Force; Montefiore Hospital.
1990–1991	P & T Subcommittee on Drug Use Evaluation; Presbyterian–University Hospital.
1991–2001	Pharmacy and Therapeutics Committee; University of Pittsburgh Medical Center (UPMC).
1991–1996	Antibiotic Subcommittee (Secretary, 1991–1995).
1993–1996	Infection Committee, UPMC.

UNIVERSITY OF PITTSBURGH UNIVERSITY-WIDE COMMITTEES

1983–1988	Provost's Advisory Committee on Undergraduate Programs.
1985–1986	Faculty Assembly.
1987–1992	Institutional Review Board for Biomedical Research.
2001–2003	Institutional Review Board.
2003–2005	Vice-Chair, Institutional Review Board.
2003–2005	Executive Committee, Institutional Review Board.

CONSULTANT:

- 1992–1993 Community Advisory Board, Hemophilia Center of Western Pennsylvania.
1989–1993 HealthAmerica of Pittsburgh, a Health Maintenance Organization (HMO).
1992–1993 Harris Laboratories, Inc., Lincoln, NE.
1993 William E. Watson & Associates, Wellsburg, WV.
1999–2000 Flaherty, Sensabaugh & Bonasso, Charleston, WV.
2001–Present Executive Advisory Board, University Pharmacotherapy Associates (UPA),
Monroeville, PA.
2006–2008 Member, Pharmacy and Therapeutics Committee, Rite-Aid Health Solutions, Moon
Township, PA.

REVIEWER:

Journal Reviewer:

- 1979–Present *U.S. Pharmacist*
1980–Present *The American Journal of Pharmaceutical Education*
1983–Present *The Annals of Pharmacotherapy (DICP)*
1984–Present *The American Journal of Health–System Pharmacy*
1984–Present *Pharmacotherapy*
1985–1993 *Clinical Pharmacy*
1985–Present *The Consultant Pharmacist*
1991–Present *Formulary* (formerly *Hospital Formulary*)
1991–Present *American Druggist*
1991–Present *The Journal of Pharmacy Technology*
1993–Present *Diabetes Care*
1995–Present *Journal of Oncology Pharmacy Practice*
2000–Present *The Journal of the American Pharmacists Association*

Reference Text Reviewer:

- 1984 *American Hospital Formulary Service Drug Information (AHFS DI)*
1984–Present *Evaluations of Drug Interactions* (Consulting Contributor)
1987–1995 *United States Pharmacopeial Dispensing Information (USP–DI)*
1998 *Concepts in Oncology Therapeutics, 2nd ed.* Bethesda, MD: ASHP, 1998.
2007 Chapter reviewer, *Pharmacotherapy: A Pathophysiologic Approach, 7th Ed.* New
York: McGraw-Hill, 2008.

Editorial Positions and Advisory Board Memberships:

- 1986–1987 Editorial Advisory Board, *U.S. Pharmacist*.
1990–1995 *Pharmacy Consult* and *Pharmacy Consult–Rx Update*, University of Pittsburgh.
2000–2002 Editorial Advisory Board, *The American Journal of Health-System Pharmacy*.
2001–Present Senior Contributing Editor, Therapeutics, *American Journal of Health-System Pharmacy*.
2006–Present Editor-in-Chief, *AccessPharmacy*, an on-line educational resource for students, faculty, and
schools of pharmacy. McGraw-Hill Medical Publishing Division, New York, NY.
www.AccessPharmacy.com.

Other:

- 1980–Present ASHP Review Panel for Contributed Papers submitted for Midyear Clinical Meetings.
1983–1985 Contributing editor, *U.S. Pharmacist*, and co–author of the Drug Information Forum.
1983–1990 Contributing editor, *Montefiore Hospital Pharmacy Newsletter*.
1984–Present ASHP Review Panel for Contributed Papers submitted for Annual Meetings.
1991–Present Abstract Reviewer for the American College of Clinical Pharmacy.
1998–Present Faculty Reviewer, School of Pharmacy Internal Scientific Review Committee.
2000 Abstract Review Panel for the AACP Academic Sections Coordinating Committee.
2002–Present Contributed Papers Review Panel for the APhA Annual Meeting.

OTHER SERVICE:

- 1982–1987 Grand Council Deputy, Beta Kappa Chapter, Kappa Psi Pharmaceutical Fraternity.
1987–1988 Chaplain, Pittsburgh Graduate Chapter of Kappa Psi Pharmaceutical Fraternity.
1990–1992 Member, Speaker's Bureau, Philadelphia College of Pharmacy and Science.
1990–1998 Member, Colony–Stimulating Factor Visiting Faculty Program, Amgen, Inc.
1999–2003 Member, Searle/Pharmacia/Pfizer Speaker's Bureau.
1999–2005 Co-Advisor, Beta Kappa Chapter, Kappa Psi Pharmaceutical Fraternity.
2001–2004 Co-Advisor for Health-System Pharmacy, Academy of Students of Pharmacy, University of Pittsburgh.

SELECTED PRESENTATIONS

1. OTC Products for Use in Children. The University of Pittsburgh School of Pharmacy 19th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 9 and 10, 1978.
2. Understanding Anticoagulant Therapy. The University of Pittsburgh School of Nursing Continuing Education series: Pharmacology Management and the Nurse: An Update; Pittsburgh, PA, November 16 and 21, 1978.
3. Problems with Heparin Therapy. The League of Intravenous Therapy Education 8th Annual Seminar; Pittsburgh, PA, February 28, 1980.
4. Food and Drug Interactions. The Indiana University of Pennsylvania School of Continuing Education program: Pharmacology Series–Update; Indiana, PA, April 21, 1980.
5. Food and Drug Interactions. The Hospital Purchasing and Material Management Association of Western Pennsylvania and the Hospital Council of Western Pennsylvania 14th Annual Hospital Educational Seminar; Monroeville, PA, April 25, 1980.
6. Chronic Obstructive Pulmonary Disease. The Pennsylvania State University statewide telephone network Continuing Education series: The Pharmacist’s Role in Pulmonary Disease–A Case Study Approach; Pittsburgh, PA, October 21, 1980.
7. Pharmacologic Agents Used in the Treatment of Chronic Respiratory Diseases. The Indiana University of Pennsylvania School of Continuing Education and the Southwestern Pennsylvania Lung Association Program: Home Care of Chronic Respiratory Disease Patients; Youngwood, PA, October 21, 1980, and October 21, 1981.
8. The Use of Antiemetics in Cancer Chemotherapy. The University of Southern Maine Bureau of Continuing Education for Nursing and the Maine Society of Hospital Pharmacists 8th Annual Nurse–Pharmacist Conference: New Developments in Cancer Therapy; Portland, ME, October 30, 1980.
9. Drug Considerations in the Gerontologic Client. The Montefiore Hospital staff development seminar: Something Old–Something New–A Program Focusing on the Gerontologic Individual; Pittsburgh, PA, October 7, 1981.
10. Third Generation Cephalosporins and Extended–Spectrum Penicillins. The League of Intravenous Therapy Education 10th Annual Seminar; Pittsburgh, PA, February 19, 1982.
11. The Choice of Antimicrobial Drugs. The Pittsburgh Chapter of the National Intravenous Therapy Association. Pittsburgh, PA, April 12, 1982.
12. New Drug Update. The University of Pittsburgh School of Pharmacy 24th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 10 and 11, 1983.
13. Sulfonamides, Tetracyclines, and Antihypertensive Medications. The Community College of Allegheny County training program for physician assistants; Pittsburgh, PA, June 15, 22, and 29, 1983.

14. 14. Drugs Used in Gastrointestinal Endoscopy: Benefits and Risks. The Pennsylvania Society of Gastrointestinal Assistants 6th Regional Educational Seminar; Monroeville, PA, September 24, 1983.
15. Cephalosporin Update. The Highland Drive Veterans Administration Hospital; Pittsburgh, PA, April 6, 1984.
16. Anticoagulant Review. The Community College of Allegheny County–North continuing education series for nurses; West View, PA, April 24, 1984.
17. New Drug Update. The University of Pittsburgh School of Pharmacy 25th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 15 and 16, 1984.
18. New Drugs in '84. The Community College of Allegheny County–North nursing program: The Contemporary Health Care Series–Pharmacology Update IV; West View, PA, September 11, 1984.
19. New Drug Update. The University of Pittsburgh School of Pharmacy 26th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 13 and 14, 1985.
20. New Drug Update. The University of Pittsburgh School of Pharmacy 27th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 5 and 6, 1986.
21. New Drug Review. The Pennsylvania Society of Hospital Pharmacists 18th Annual Assembly; Champion, PA, October 10, 1986.
22. New Drug Developments. The American Pharmaceutical Association Region 2 Midyear Regional Meeting; Pittsburgh, PA, November 16, 1986.
23. Food and Drug Interactions. The University of Pittsburgh School of Medicine Continuing Medical Education Outreach Program: Woodville State Hospital, Carnegie, PA, January 9, 1987; Torrance State Hospital, Blairsville, PA, May 28, 1987; Somerset State Hospital, Somerset, PA, May 29, 1987. The Cambria–Somerset–Bedford Pharmacy Society; Johnstown, PA, October 11, 1987.
24. New Drug Update. The University of Pittsburgh School of Pharmacy 28th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 12 and 13, 1987. The Cambria–Somerset–Bedford Pharmacy Society; Johnstown, PA, June 7, 1987.
25. Review of Basic Pharmacokinetic Concepts. The University of Pittsburgh School of Medicine Continuing Medical Education Outreach Program: Torrance State Hospital, Blairsville, PA, November 12, 1987; Woodville State Hospital, Carnegie, PA, December 4, 1987.
26. Are We Still “Poisoning Patients with Intravenous Theophylline”? Medical Grand Rounds at Montefiore Hospital; Pittsburgh, PA, February 18, 1988.
27. New Drug Update. The University of Pittsburgh School of Pharmacy 29th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 10 and 11, 1988.
28. Pharmacodynamic Monitoring with Etoposide. The Fourth Annual Pittsburgh Pharmacodynamic Conference: The Pharmacodynamics of Immunomodulating Drugs; Pittsburgh, PA, May 25–26, 1988.

29. Emerging Concepts in the Treatment of Hypokalemia. A pharmacy continuing education seminar; Morgantown, WV, September 21, 1988.
30. The Role of Plasma Etoposide Concentration Monitoring in Bone Marrow Transplantation. The Bristol–Myers Oncology Division District 2004 Annual Preceptorship; Pittsburgh, PA, October 12, 1988.
31. This Year’s New Drugs: Focus on the Best. The University of Pittsburgh School of Pharmacy 30th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 9 and 10, 1989. The Cambria–Somerset–Bedford Pharmacy Society; Johnstown, PA, November 5, 1989.
32. Cytoprotective Agents for Prevention of NSAID–Induced Gastric Damage. Medical Grand Rounds at Montefiore Hospital; Pittsburgh, PA, June 1, 1989.
33. Cytoprotective Agents for the Prevention of NSAID–Induced Gastropathy. Pharmacy continuing education programs: Pittsburgh, PA, June 26 and August 30, 1989; Mount Pleasant, PA, June 10, 1990; the South Central Pennsylvania Pharmaceutical Association, Chambersburg, PA, February 6, 1991; the Westmoreland County Pharmaceutical Association, Delmont, PA, June 13, 1991; the Baltimore Metropolitan Pharmaceutical Association, Baltimore, MD, July 21, 1991; Braddock Medical Center, Braddock, PA, November 6, 1991; Pittsburgh, PA, November 24, 1991.
34. Update on Hypertension. The Fayette County Pharmaceutical Association; Charleroi, PA, October 22, 1989.
35. Antibiotic Use in the Immunocompromised Patient. The Pittsburgh Cancer Institute course: Fundamentals of Chemotherapy–A Course for Nurses and Pharmacists; Pittsburgh, PA, November 20, 1989; March 26 and October 19, 1990.
36. Host Defense Mechanisms and Infection. The Beaver County Pharmaceutical Association; Beaver, PA, January 18, 1990.
37. A Forum on Generic Drugs. A patient education program for the Cardiac Support Group of Montefiore Hospital; Pittsburgh, PA, March 26, 1990.
38. Whatever Happened to the “Stepped–Care” Approach to the Treatment of Hypertension? Pharmacy continuing education: Giant Eagle Pharmacies, Greentree, PA, March 28 and 29, 1990. Specialized Pharmacy Services, Pittsburgh, PA, June 20, 1991.
39. Perspectives on New Drugs: The Good, the Bad, and the Mediocre. University of Pittsburgh School of Pharmacy 31st Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 8 & 9, 1990.
40. Antibiotic Use in the Immunocompromised Patient. The Pittsburgh Cancer Institute programs: Cancer Care Update for Nurses and Pharmacists, Pittsburgh, PA, October 11, 1990; A Comprehensive Introduction to Chemotherapy–A Patient Management Approach, Pittsburgh, PA, February 14 and April 4, 1991.
41. Evaluation of New Drugs. The Western Pennsylvania Society of Hospital Pharmacists Clinical Skills Seminar and Workshop; Pittsburgh, PA, October 19, 1990.

42. Colony–Stimulating Factors: From Laboratory to Clinical Application. Continuing education for pharmacists: Columbia, SC, November 27, 1990; Indianapolis, IN, November 28, 1990; Lahey Clinic, Burlington, MA, January 28, 1991; Newton–Wellsley Hospital, Newton Lower Falls, MA, January 29, 1991; the Johns Hopkins Hospital, Baltimore, MD, May 15, 1991; the University of Medicine and Dentistry, Newark, NJ, May 29, 1991; the University of Pittsburgh Medical Center, Pittsburgh, PA, July 24, 1991; Southeastern Chapter of PSHP, Harrisburg, PA, September 11, 1991.
43. Newly–Approved Parenteral Products: What is Their Role in Therapy? The League of Intravenous Therapy Education 19th Annual seminar; Pittsburgh, PA, February 6, 1991.
44. Colony–Stimulating Factors. The Pittsburgh Cancer Institute program: Current Concepts in Biotherapy; Pittsburgh, PA, March 28, 1991 and April 23, 1992.
45. Colony–Stimulating Factors and Their Impact on Future Cancer Therapy. The Annual Meeting of the Indiana Society of Hospital Pharmacists; Indianapolis, IN, April 20, 1991.
46. New Drug Update: The Picks and the Pans. The University of Pittsburgh School of Pharmacy 32nd Annual Spring Continuing Education Seminar; Pittsburgh, PA, April 30, 1991. The Cambria–Somerset–Bedford Pharmacy Society; Johnstown, PA, May 5, 1991.
47. Role of Hematopoietic Growth Factors in Bone Marrow Transplantation. The Spring Conference of the Eastern Cooperative Oncology Group; Pittsburgh, PA, June 11, 1991.
48. Clinical Application of Colony–Stimulating Factors. The Pittsburgh Cancer Institute program: A Comprehensive Introduction to Chemotherapy–A Patient Management Approach; Pittsburgh, PA, September 27, 1991; January 30, March 12, September 15, & November 24, 1992; April 27, September 14, & November 23, 1993; March 15 & September 30, 1994, March 3 & October 3, 1995; March 5 & October 2, 1996.
49. The Role of Calcium Channel Blockers in the Management of Hypertension. The Centre County Pharmaceutical Association; Burnham, PA, October 17, 1991. The Capitol Area Pharmaceutical Association; Harrisburg, PA, November 7, 1991.
50. Arthritis Medication Update. The Pennsylvania Pharmaceutical Association symposium: Update on Arthritis–Patient Care Issues for the Pharmacist; Pittsburgh, PA, November 23, 1991.
51. The Role of Immunosuppressants in the Treatment and Prevention of Graft–Versus–Host Disease. The 26th Annual ASHP Midyear Clinical Meeting symposium: Immunology and Bone Marrow Transplantation; New Orleans, LA, December 12, 1991.
52. Review of New Drugs Approved in 1991. The Northwestern Chapter of the Pennsylvania Society of Hospital Pharmacists; Erie, PA, January 21, 1992.
53. A Clinical Overview of Colony–Stimulating Factors. The American Cancer Society and Creighton University symposium: Interdisciplinary Perspectives for the Colony–Stimulating Factors–Clinical and Economic Considerations; Omaha, NE, April 15, 1992.
54. Recent New Drug Approvals: Is More Necessarily Better? The University of Pittsburgh 33rd Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 12, 1992. The Cambria–Somerset–Bedford Pharmacy Society; Johnstown, PA, May 17, 1992.

55. A Clinical Overview of Colony–Stimulating Factors. The Northeast Tennessee Society of Hospital Pharmacists; Johnson City, TN, October 8, 1992.
56. Unlabeled Uses of Approved Drugs: Clinical Considerations. The Western Pennsylvania Society of Hospital Pharmacists; Pittsburgh, PA, January 27, 1993.
57. Newly–Approved Parenteral Drugs. The League of Intravenous Therapy Education 21st Annual Seminar; Pittsburgh, PA, February 18, 1993.
58. New Drugs of 1992. The University of Pittsburgh 34th Annual Spring Continuing Education Seminar; Pittsburgh, PA, May 18, 1993.
59. Management of NSAID–induced Gastropathy: Patient and Drug Selection *and* When Should Prokinetic Agents Be Used in Gastroesophageal Reflux Disease? The University Pharmacotherapy Associates symposium: Controversies in the Management of Upper GI Diseases: What the Pharmacist Needs to Know; Pittsburgh, PA, March 7, 1994.
60. New Drug Approvals: Separating the Innovations from the Duplications. The University of Pittsburgh 35th Annual Spring Continuing Education Seminar; Pittsburgh, PA, April 30, 1994.
61. Blood Substitutes: Clinical, Regulatory, and Economic Considerations. The National Pharmacy Forum: Immune Modulation in Transplantation and Autoimmune Diseases: Therapeutic Advances and Economic Considerations; Dallas, TX, May 20–22, 1994.
62. What You Need to Know about the 1994 New Drug Approvals. The University of Pittsburgh 36th Annual Spring Continuing Education Seminar: The Wurdack Lectures; Pittsburgh, PA, April 9, 1995.
63. New Frontiers in Anticoagulant and Antiplatelet Therapy (Moderator). University Pharmacotherapy Associates; The Annual Meeting of the American Society of Hospital Pharmacists; Philadelphia, PA. June 5, 1995.
64. New Drug Update: What You Need to Know About the 1995 New Drug Approvals. The Pennsylvania Society of Hospital Pharmacists and the West Virginia Society of Hospital Pharmacists 27th Annual Assembly; Champion, PA, October 20, 1995.
65. Changing Standards in the Pharmacotherapy of Acid–Peptic Disorders. The Annual Paul J. Wurdack Fall Continuing Education Seminar; Pittsburgh, PA, November 5, 1995.
66. New Drug Update: What You Need to Know About the 1995–1996 New Drug Approvals. Hollidaysburg, PA, April 21, 1996.
67. Cardiovascular, Endocrine, and Dermatological Medications. The ASHP Annual Meeting symposium: New Drug Update; San Diego, CA, June 6, 1996.
68. New Drug Update: What You Need to Know about the 1995–1996 New Drug Approvals. State College, PA, September 8, 1996.
69. New Drugs on the Horizon. The PSHP 28th Annual Assembly, Hershey, PA, October 4, 1996.

70. Developing Case Studies for the Pharmacy Curriculum. Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, November 25, 1996.
71. The Practice of Pharmacy in the 21st Century: A Panel Discussion The Allegheny County Pharmaceutical Association; Pittsburgh, PA, April 17, 1997.
72. Positioning Integrated Health–Systems for Future Success: Focus on Quality and Pharmaceutical Care (Moderator). Exhibitor’s Theater, the ASHP Annual Meeting; Minneapolis, MN, June 2, 1997.
73. A Window of Opportunity: PSHP Presidential Installation Address. The PSHP 29th Annual Assembly; Lancaster, PA, October 9, 1997.
74. The State of the Society: a PSHP Presidential Address. The PSHP Midwinter Conference XIX; Valley Forge, PA, March 19, 1998.
75. The President’s State of the Society Address. The PSHP 30th Annual Assembly, Lancaster, PA, October 15, 1998.
76. New Treatment Options in the Management of Arthritis: Focus on COX-2 Selective Inhibitors. Presented to: medical residents of UPMC and St. Francis Hospital, Pittsburgh, PA, March 16, 1999; the Pennsylvania Society of Health-System Pharmacists Midyear Meeting XX, Pittsburgh, PA, March 18, 1999; the medical residents at West Virginia University Medical Center, Morgantown, WV, March 30, 1999; pharmacists of Tops Markets, Hudson, OH, May 5, 1999; primary care physicians, West Middlesex, PA, May 7, 1999; family practice physicians, Pittsburgh, PA, May 8, 1999; physician assistants and psychiatrists at the Benedum Geriatric Center, Pittsburgh, PA, May 28, 1999; the pharmacy staff of Howard General Hospital, Columbia, MD, June 15, 1999; community pharmacists, Monroeville, PA, July 29, 1999; internal medicine physicians, Beallsville, PA, August 4, 1999; emergency department physicians of the Washington, PA, Hospital, Bethel Park, PA, September 8, 1999; the Bucks County Pharmacists Association, Levittown, PA, September 15, 1999; the Tioga-Potter County Pharmacists Association, Wellsboro, PA, November 7, 1999. Physicians, nurse practitioners, and pharmacists of the Veterans Affairs Hospital, Philadelphia, PA, November 10, 1999; The Montgomery County Pharmacists Association, Horsham, PA, November 16, 1999; UPMC Orthopedic Surgery Residents, Pittsburgh, PA, December 21, 1999; Pharmacists at Pharmerica, Inc., Beltsville, MD, May 10, 2000; Pharmacists of the regional AHEC, Cumberland, MD, July 16, 2000; The Maryland Chapter of the American Society of Consultant Pharmacists 7th Annual Mid-Atlantic Conference, Cumberland, MD, August 18, 2000; the monthly meeting of the local chapter of Alpha Zeta Omega, Timonium, MD, September 17, 2000; physicians in the Baltimore-Washington, DC area, October 15, 2000.
77. New Treatment Options in the Management of Arthritis: An In-Depth Discussion. A two-hour continuing education program presented to: The Ocala and Walton County Pharmaceutical Association, Crestview, FL, March 25, 1999; the Potomac Region of the Virginia Pharmacists’ Association, Falls Church, VA, April 12, 1999; the Indo-American Pharmacists’ Association, Columbia, MD, May 2, 1999; Pittsburgh-area pharmacists, Hampton Township, PA, June 17, 1999; The Pennsylvania Pharmacists Association Annual Meeting, Hershey, PA, July 16, 1999; Pharmacists in Clearfield, PA, October 28, 1999; The Tioga-Potter County Pharmacists Association, Wellsboro, PA, November 7, 1999; Pharmacists of Rite-Aid, Inc., Beachwood, OH, May 16 & 17, 2000.
78. Clinical Writing From Both Sides of the Fence: Perspectives as a Writer and Editor. Presented at the University of Pittsburgh School of Pharmacy Research Retreat, Pittsburgh, PA, August 26, 1999.

79. COX-2 Selective Inhibitors: A Summary of Data from Recent Clinical Trials. A continuing education program presented to physicians, physician assistants, and/or nurse practitioners: In Pittsburgh, PA, October 25 & 28, November 8, 11, 21, 22, and December 6, 2000; February 9 & 21, 2001; and May 14, 2002. Also presented in Erie, PA, November 14, 2000; Beaver Falls, PA, November 16, 2000; Farmington, PA, May 5, 2001; Wexford, PA, August 5, 2001; Mount Pleasant, PA, October 25, 2001; Wilkes-Barre, PA, November 2, 2001; Cumberland, MD, February 27, 2002; Dubois, PA, March 21, 2002; Monroeville, PA, April 30, 2002.
80. COX-2 Technology: A Year in Review—The Promise and the Potential. A continuing education program presented to the Washington, D.C. Pharmaceutical Association, Washington, D.C., November 30, 2000.
81. Should I Consider a Career in Academia? (Organizer/Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 5, 2000.
82. Case Reports: How to Write ‘em Like you See ’em. Presentation at the pharmacy resident research seminar to students, residents, and faculty in the Department of Pharmacy and Therapeutics, University of Pittsburgh, January 12, 2001; April 4, 2002. Also presented to the pharmacy staff of Ruby Memorial Hospital, Morgantown, WV, March 26, 2008.
83. Your Rx for Success in an Academic Career (Organizer and Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, New Orleans, LA, December 5, 2001. Repeated as a special program at the AACP Annual Meeting, Kansas City, MO, July 16, 2002.
84. Celecoxib in Acute Pain and Primary Dysmenorrhea. Presented to neurologists and family practice physicians in Pittsburgh, PA, January 26, February 9, February 15, & February 25, 2002.
85. The Publishing Experience: An Author’s Perspective. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled “Publishing with ASHP: A Cross-Media Perspective,” Atlanta, GA, December 10, 2002.
86. Is an Academic Career in My Future? (Organizer and Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Atlanta, GA, December 11, 2002.
87. Case Studies in the Management of Hyperlipidemia: A Panel Discussion. Presented to physicians in Pittsburgh, PA, October 1, 2003.
88. Pharmaceutical Care: The Impossible Takes a Little Longer. An invited presentation for the Howard C. Ansel Distinguished Clinical Lectureship and Symposium as part of the Centennial Celebration at the University of Georgia College of Pharmacy, Athens, GA, October 15, 2003.
89. Get the Word Out! Tips for Medical Writing and Publishing. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled “Publishing with AJHP: A Step-by Step Approach,” New Orleans, LA, December 8, 2003.
90. A Clinician’s Roadmap to Success in Academia (Organizer/Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, New Orleans, LA, December 10, 2003.
91. Designing the Curriculum Today to Improve the Curriculum Tomorrow. Presented to the faculty of Misr International University Faculty of Pharmacy, Cairo, Egypt, May 20, 2004.

92. Preparing a Manuscript for Journal Submission. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled "How to Write and Review for Biomedical Journals," Orlando, FL, December 7, 2004.
93. The Top 10 Reasons to Consider a Career in Academia (Organizer/Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Orlando, FL, December 7, 2004.
94. Designing the Curriculum Today to Improve the Curriculum Tomorrow. Presented to the Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan, March 8, 2005; presented to the Department of Pharmacy, Fukuoka University Hospital, March 10, 2005; presented to the Japanese Society of Hospital Pharmacists and the Japanese Pharmaceutical Society, Kagoshima, Japan, March 11, 2005.
95. Pharmaceutical Care: The Future of Pharmacy Practice. Presented to the Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan, March 9, 2005; presented to the Kagoshima Society of Hospital Pharmacists, Kagoshima, Japan, March 12, 2005; presented to the Department of Pharmacy, Nagasaki University Hospital, Nagasaki, Japan, March 15, 2005.
96. Teaching and Learning in the New Pharmacy Curriculum. Presented to the Department of Pharmacy, Nagasaki University Hospital, Nagasaki, Japan, March 16, 2005.
97. Preparing a Manuscript for Journal Submission. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled "How to Write and Review for Biomedical Journals," Las Vegas, NV, December 6, 2005.
98. Teaching, Research, and Service: Three Aces for your Academic Career (Organizer and Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Las Vegas, NV, December 6, 2005.
99. Tipping Points in Pharmacy: Four Trends that will Change Practice. Presented to the Ohio-Marshall County Pharmacists Association (OMOCPA), Wheeling, WV, March 5, 2006.
100. A Clinician's Guide to Success in Academia (Organizer and Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Anaheim, CA, December 5, 2006.
101. Preparing a Manuscript for Journal Submission. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled "How to Write and Review for Biomedical Journals," Anaheim, CA, December 6, 2006.
102. Providing and Optimizing Care in the 21st Century. Presented as the keynote presentation at the Saudi Aramco Medical Services Organization (SAMSO) national pharmacy symposium entitled "A Quest for Optimal Pharmacotherapy," Dhahran, Saudi Arabia, March 7, 2007.
103. Tipping Points in Pharmacy: Trends That Will Change Practice. Presented at the Saudi Aramco Medical Services Organization (SAMSO) national pharmacy symposium entitled "A Quest for Optimal Pharmacotherapy," Dhahran, Saudi Arabia, March 8, 2007.
104. Lessons for Success from the Wizard of Oz. The Sister M. Gonzales Duffy Lecture Award, presented at the PSHP 39th Annual Assembly, Mars, PA, October 12, 2007.

105. Teaching and Learning in the New Pharmacy Curriculum. Presented to the Tokushima University Faculty of Pharmaceutical Sciences, Tokushima, Japan, October 24, 2007.
106. Preparing a Manuscript for Journal Submission. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled “How to Write and Review for Biomedical Journals 2007,” Las Vegas, NV, December 4, 2007.
107. Career Opportunities in Academic Pharmacy (Session Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Las Vegas, NV, December 4, 2007.
108. Tips for Writing Stellar Review Articles, Case Reports, Editorials, and Letters. Presented at the ACCP Spring Forum as part of the two-house session entitled “Scientific Series B–Being Productive in Scholarly Activity: Part I,” Phoenix, AZ, April 8, 2008.
109. Is Board Certification in My Future? Presented at the 27th Annual Eastern States Conference for Pharmacy Residents and Preceptors, Hershey, PA, April 30, 2008.
110. Lessons for Success from the Wizard of Oz. Presented at the 27th Annual Eastern States Conference for Pharmacy Residents and Preceptors, Hershey, PA, April 30, 2008.
111. Publish or Perish: Taking your Ideas to Print. Presented at the Pennsylvania Society of Health-System Pharmacists Annual Assembly, Hershey, PA, October 2, 2008.
112. A Clinician’s Guide to a Successful Academic Career (Organizer and Moderator). A two-hour program sponsored by AACP at the ASHP Midyear Clinical Meeting, Orlando, FL, December 9, 2008.
113. Preparing a Manuscript for Journal Submission. Presented at the ASHP Midyear Clinical Meeting as part of the two-hour session entitled “How to Write and Review for Biomedical Journals 2008,” Orlando, FL, December 10, 2008.
114. Publishing and the Frontline Pharmacist. Panel discussion at the ASHP Midyear Clinical Meeting sponsored by the Section of Inpatient Practitioners, Orlando, FL, December 10, 2008.

PUBLICATIONS

REVIEW AND NON-RESEARCH ARTICLES:

1. Schwinghammer TL, Kitt D, Lysinger C. A review of lithium therapy. U.S. Pharm. 1976; 1(2):40–5.
2. Schwinghammer TL. Your role in the treatment of cold-related injuries. U.S. Pharm. 1978; 3(1):48–53, 56.
3. Schwinghammer TL, Britton HL. Adverse effects of drugs on the eye. U.S. Pharm. 1979; 4(1):49, 53–8, 60.
4. Schwinghammer TL. Antiemetics: choosing from the alternatives. Hosp Formul. 1980; 15(1):38–9, 42–3, 47–8, 51.

REVIEW AND NON-RESEARCH ARTICLES: (continued)

5. Schwinghammer TL. Current treatment of tic douloureux. U.S. Pharm. 1980; 5(4):28–31. Reprinted in condensed form in 20/20. 1980; 7:98–9.
6. Giovannitti C, Schwinghammer TL. Food and drugs: managing the right mix for your patient. Nursing '81. 1981; 11(7):26–31.
7. Schwinghammer TL. Drug interactions with cimetidine. Am J Hosp Pharm. 1981; 38:1976–8.
8. Schwinghammer TL. Drug withdrawal syndromes. U.S. Pharm. 1982;7(3):35–6, 38, 40–5, 47–8, 51–2.
9. Schwinghammer TL. The new extended–spectrum penicillins. U.S. Pharm. 1982; 7(9):78–84.
10. Fischer JM, Schwinghammer TL. AIDS rounds: enhancement of tricyclic antidepressants by thyroid. Drug Intell Clin Pharm. 1983; 17:718–9.
11. Responses to 135 questions on a wide variety of drug–related topics were published in the monthly Drug Information Forum column of U.S. Pharm., January, 1983 through April, 1985.
12. Schwinghammer T. Ketoprofen (Orudis). P & T Sharing Service: Pennsylvania Society of Hospital Pharmacists. 1986; 3:36–40.
13. Schwinghammer TL, Kroboth PD. Basic concepts in pharmacodynamic modeling. J Clin Pharmacol. 1988; 28:388–94.
14. Kroboth PD, Schwinghammer TL. Controversy III: Modeling. J Clin Pharmacol. 1988; 28:885–8.
15. Schwinghammer TL, Giovannitti C. A guide to important food and drug considerations. Nursing 88. 1988; 18(8):40.
16. Schwinghammer TL. Update on otitis media and its treatment. Pharm Focus. 1989; 2(1):1–5, 12.
17. Schwinghammer TL. Nicardipine (Cardene). P & T Sharing Service: Pennsylvania Society of Hospital Pharmacists 1990; 7:1–5.
18. Schwinghammer TL. Misoprostol: first agent approved for prevention of NSAID–induced ulcers. Pharm Consult. 1990; 1(1):3.
19. Schwinghammer TL. Nicardipine: just another calcium channel antagonist? Pharm Consult. 1990; 1(2):6–7.
20. Schwinghammer TL. The FDA's rating system for new drugs. Pharm Consult. 1990; 1(2):10–1. Reprinted in the APhA national publication Pharmacy Update. 1990; 2(2):8–9.
21. Schwinghammer TL. New procedures speed access to experimental drugs. Pharm Consult. 1991; 2(1):6–8. Summarized in University Medicine 1991; 3(3):5–6.
22. Schwinghammer TL. The myeloid colony–stimulating factors: focus on G–CSF. Pharm Consult. 1991; 2(2):1–4.

REVIEW AND NON-RESEARCH ARTICLES: (continued)

23. Schwinghammer TL. The myeloid colony–stimulating factors: focus on sargramostim. Pharm Consult. 1991; 2(3):1–3.
24. Schwinghammer TL, Giovannitti C. Guide to selected food and drug considerations. In: McGovern K. 10 golden rules for administering drugs safely. Nursing 92. 1992; 22(3):55.
25. Schwinghammer TL. The myeloid colony–stimulating factors: focus on sargramostim. P & T. 1992; 17(4):611–3.
26. Schwinghammer TL. Focus on drug therapy: H₂ antagonists and GERD. Am Druggist. 1992; 206(5):34–41.
27. Schwinghammer TL, Giovannitti C. Guide to selected food and drug considerations. In: Benner J, ed. Med errors: how to keep your patients safe. Springhouse: Nursing 93, 1993;11.
28. Schwinghammer TL, Bloom EJ. Pharmacologic prophylaxis of acute graft–versus–host disease after allogeneic marrow transplantation. Clin Pharm. 1993; 12:736–61.
29. Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high–dose cyclophosphamide therapy. Ann Pharmacother. 1995;29:918–21.
30. Vanscoy GJ, Rihn TL, Schwinghammer T, eds. New frontiers in antithrombosis: acute coronary syndromes. University Pharmacotherapy Associates, Chicago: 1998;3(1): 1-5.
31. Vanscoy GJ, Rihn TL, Schwinghammer TL, eds. Horizons in Antithrombosis. University of Pittsburgh School of Pharmacy, March 1999; March 2000.
32. Schwinghammer TL. Final report of the 2004–2005 Council of Faculties. Am J Pharm Educ. 2005;69(5) Article S13.
33. Draugalis JR, DiPiro JT, Zeolla MM, Schwinghammer TL. A career in academic pharmacy: Opportunities, challenges, and rewards. Am J Pharm Educ. 2006;70(1):Article 17:1–15. (Online Date August 10, 2004)

CASE REPORTS:

1. Britton HL, Schwinghammer TL. Phenytoin–induced hyperglycemia. Drug Intell Clin Pharm. 1980; 14:544–7.
2. Schwinghammer TL, Howrie DL. Phenytoin–induced lymphadenopathy. Drug Intell Clin Pharm. 1983; 17:460–2.
3. Schwinghammer TL, Kroboth FJ, Juhl RP. Extrapyrimal reaction secondary to oral promethazine. Clin Pharm. 1984; 3:83–5.
4. Derry CL, Schwinghammer TL. Agranulocytosis associated with sulfasalazine. Drug Intell Clin Pharm. 1988; 22:139–42.

CASE REPORTS: (continued)

5. Howrie DL, Schwinghammer TL, Wollman M. Use of i.v. immune globulin for treatment of phenytoin-induced thrombocytopenia. Clin Pharm. 1989; 8:734-7.

RESEARCH ARTICLES:

1. Schwinghammer TL. Videotaped introductory instruction in the physical examination for clinical clerkship students. Am J Pharm Educ. 1981; 45:33-5.
2. Britton HL, Schwinghammer TL, Romano MJ. Cost containment through restriction of cephalosporins. Am J Hosp Pharm. 1981;38:1897-1900.
3. Fraley DS, Britton HL, Schwinghammer TL, Kalla R. Effect of cimetidine on steady-state serum digoxin concentrations. Clin Pharm. 1983; 2:163-5.
4. Schwinghammer TL. Prescribing of oral metoclopramide for non-approved indications. Drug Intell Clin Pharm. 1984; 18:317-9.
5. Schwinghammer TL, Juhl RP, Dittert LW, Melethil S, Kroboth FJ, Chungi VS. Comparison of the bioavailability of oral, rectal and intramuscular promethazine. Biopharm Drug Dispos. 1984; 5:185-94.
6. Howrie DL, Schwinghammer TL. Cephalosporin use and restriction in pediatric hospitals. Am J Hosp Pharm. 1985; 42:1576-8.
7. Schwinghammer TL, Romano MJ, Wing EJ. Cost savings associated with use of gentamicin versus tobramycin. Am J Hosp Pharm. 1985; 42:1745-9.
8. Venkataramanan R, Perez HD, Schwinghammer T, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE. Effect of bile on cyclosporine absorption in dogs. Res Comm Chem Pathol Pharmacol. 1986; 53:137-40.
9. Howrie DL, Schwinghammer TL. Antibiotic restriction programs in pediatrics: a survey of infectious disease specialists. Hosp Formul. 1987; 22:797-9, 802.
10. Wang C, Burckart G, Ptachcinski R, Venkataramanan R, Schwinghammer T, Hakala T, Griffith B, Hardesty R, Shaddock R, Knapp J, Van Thiel DH, Makowka L, Starzl TE. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc. 1988; 20 (Suppl 2, No. 2):591-6.
11. Schwinghammer TL, Romano MJ, Gilliland BF, Gentile CJ. Audit aims for appropriate use of injectable metoclopramide. Drug Utilization Review. 1988; 4:1s-4s.
12. Schwinghammer TL, Romano MJ, Gilliland BF, Gentile CJ. Use review of intravenous aminophylline. Infusion. 1989; 13(1):3-6.
13. Schwinghammer TL, Norden CW, Gill E. Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects. J Clin Pharmacol. 1990; 30:893-9.
14. Schwinghammer TL, Mabon B, Romano MJ, Gilliland BF, Norden CW. Costlier antibiotic may actually be cheaper therapy. Drug Utilization Review. 1990; 6:137-44.

RESEARCH ARTICLES: (continued)

15. Rosenfeld CS, Przepiorka D, Schwinghammer TL, Buck DS, Bloom EJ, Shadduck RK. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. Exp Hematol. 1991; 19:317-21.
16. Schwinghammer TL, Antal EJ, Kubacka RT, Hackimer ME, Johnston JM. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Clin Pharm. 1991; 10:532-8.
17. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Venkataramanan R, Shadduck RK. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplantation. 1991; 7:461-5.
18. Schwinghammer TL, Przepiorka D, Wang CP, Venkataramanan R, Burckart GJ, Rosenfeld CS, Shadduck RK. Kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br J Clin Pharmacol. 1991; 32:323-8.
19. Gilliland BF, Stanislav GH, Constantin JJ, Schwinghammer TL. Program for reviewing returned medications. Am J Hosp Pharm. 1992; 49:860-3.
20. Stiff DD, Schwinghammer TL, Corey SE. High-performance liquid chromatographic analysis of etoposide in plasma using fluorescence detection. J Liq Chromatog. 1992; 15:863-73.
21. Schwinghammer TL, Gilliland BF, Hirsh J. Triazolam use in a university medical center. Am J Hosp Pharm. 1992; 49:2939-43.
22. Schwinghammer TL, Fleming RA, Rosenfeld CS, Shadduck RK, Stewart CF. Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemother Pharmacol. 1993; 32:273-8.
23. Schwinghammer TL, Wiggins LE, Burgunder MR, Michell TE, Bailey WL. Adverse reactions related to i.v. infusion of high-dose cyclophosphamide in bone marrow transplant patients. Am J Hosp Pharm. 1994; 51:2419-21.
24. Schwinghammer TL, Kroboth, PD, Szajna JM, Dudjak LA, Brown FH. Documentation of interventions on a multidisciplinary health care team. Continuing Education Series in Pharmacy & Managed Care. 1995; 3(4):8, 10-12, 14.
25. Schwinghammer TL, Bloom EJ, Rosenfeld CS, Wilson WJ, Przepiorka D, Shadduck RK. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease. Bone Marrow Transplantation. 1995; 16:147-54.
26. Kelley KA, DeBisschop M, Donaldson AR, Hogue VW, Joyner PU, Schwinghammer TL, Riffie WH. Student engagement and the professionalization of pharmacy students. (Submitted November 8, 2008).
27. American Society of Health-System Pharmacists. Capacity of hospitals to partner with academia to meet experiential education requirements for pharmacy students. Am J Health Syst Pharm. 2008;65:2045-6. Full report published online at www.ajhp.org. Am J Health Syst Pharm 2008;65:e53-71. Also published in Am J Pharm Educ 2008;72(5) Article 17. Role: Member of Advisory Panel that provided input about questionnaire design and the report.

BOOKS AND MONOGRAPHS:

1. Fischer JM, Schwinghammer TL, Strauss S. The pharmacist's answer book: In-depth responses to common questions about drug therapy. Lancaster: Technomic Publishing Company Inc., 1986.
2. Schwinghammer TL, ed. Directions for pharmaceutical care in Pennsylvania. Proceedings of an invitational conference on pharmaceutical care; 1992 Oct 29–30; Harrisburg. Philadelphia: Pennsylvania Society of Hospital Pharmacists, 1993.
3. Schwinghammer TL, ed. Pharmacotherapy: A patient-focused approach. 1st ed. Stamford, CT: Appleton & Lange, 1997.
4. Schwinghammer TL, ed. Instructor's guide to accompany pharmacotherapy: A patient-focused approach. 1st ed. Stamford, CT: Appleton & Lange, 1997.
5. Schwinghammer TL, ed. The second statewide pharmaceutical care conference: responding to changes in the health care environment. Proceedings of an invitational conference; 1996 Nov 15–16; Harrisburg. Philadelphia: Pennsylvania Society of Health-System Pharmacists, 1997.
6. Wells, BG, DiPiro JT, Schwinghammer TL, Hamilton CW, eds. Pharmacotherapy handbook. 1st ed. Stamford, CT: Appleton & Lange, 1998.
7. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Schwinghammer TL, Anderson PO, Knoben JE. Pharmacotherapy.complete: An integrated CD-ROM containing *Pharmacotherapy: a pathophysiologic approach* (3rd ed.), *Pharmacotherapy: a patient-focused approach (Casebook and Instructor's Guide)*, and *Handbook of clinical drug data* (8th ed.). Stamford CT: Appleton & Lange, 1998.
8. Wells, BG, DiPiro JT, Schwinghammer TL, Hamilton CW, eds. Pharmacotherapy handbook. 2nd ed. Stamford, CT: Appleton & Lange, 2000.
9. Schwinghammer TL, ed. Pharmacotherapy casebook: A patient-focused approach. 2nd ed. Stamford, CT: Appleton & Lange, 2000.
10. Schwinghammer TL, ed. Instructor's guide to accompany pharmacotherapy casebook: A patient-focused approach. 2nd ed. Stamford, CT: Appleton & Lange, 2000.
11. Section Editor for Rheumatic Disorders. In: Ginsburg DB. ASHP's PharmPrep: Case-Based Board Review. 1st ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2001.
12. Schwinghammer TL, ed. Pharmacotherapy casebook: A patient-focused approach. 5th ed. New York, NY: McGraw-Hill, 2002.
13. Schwinghammer TL, ed. Pharmacotherapy casebook instructor's guide on CD-ROM. 5th ed. New York, NY: McGraw-Hill, 2002.
14. Wells, BG, DiPiro JT, Schwinghammer TL, Hamilton CW, eds. Pharmacotherapy handbook. 5th ed. New York, NY: McGraw-Hill, 2003.
15. Section Editor for Rheumatic Disorders. In: Ginsburg DB. ASHP's PharmPrep: Case-Based Board Review. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004.

BOOKS AND MONOGRAPHS: (continued)

16. Schwinghammer TL, ed. Pharmacotherapy casebook: A patient–focused approach. 6th ed. New York, NY: McGraw-Hill, 2005.
17. Schwinghammer TL, ed. Pharmacotherapy casebook instructor’s guide on CD-ROM. 6th ed. New York, NY: McGraw-Hill, 2005.
18. Wells, BG, DiPiro JT, Schwinghammer TL, Hamilton CW, eds. Pharmacotherapy handbook. 6th ed. New York, NY: McGraw-Hill, 2006.
19. Section Editor for Rheumatic Disorders. In: Ginsburg D, ed. ASHP’s PharmPrep [cd-rom]. 3rd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007. www.pharmpreponline.com.
20. Chisholm MA, Wells BG, Schwinghammer TL, Malone P, Kolesar JM, Rotschafer J, DiPiro JT, eds. Pharmacotherapy Principles & Practice. 1st ed. New York, NY: McGraw-Hill, 2008.
21. Schwinghammer TL, Koehler JM, eds. Pharmacotherapy casebook: A patient–focused approach. 7th ed. New York, NY: McGraw-Hill, 2008. Comprehensive instructor’s guide available online.
22. Wells, BG, DiPiro JT, Schwinghammer TL, DiPiro C, eds. Pharmacotherapy handbook. 7th ed. New York, NY: McGraw-Hill, 2008.
23. Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone P, Kolesar JM, DiPiro JT, eds. Pharmacotherapy Principles & Practice, 2nd ed. McGraw-Hill: New York. In preparation; scheduled for publication in March 2010.

BOOK CHAPTERS:

1. Kroboth PD, Schwinghammer TL, Bergstrom RF. H–2 antagonists: choosing a model. In: Kroboth PD, Smith RB, Juhl RP, eds. Pharmacokinetics and Pharmacodynamics: Current Problems, Potential Solutions. Cincinnati: Harvey Whitney Books Incorporated, 1988:10–28.
2. Anon. Preface. In: Schwinghammer TL, ed. Pharmacotherapy: a patient–focused approach. 1st ed. Stamford, CT: Appleton & Lange, 1997:xi.
3. Schwinghammer TL. Introduction: how to use this casebook. In: Schwinghammer TL, ed. Pharmacotherapy: a patient–focused approach. 1st ed. Stamford, CT: Appleton & Lange, 1997:1–5.
4. Anon. Preface. In: Schwinghammer TL, ed. Pharmacotherapy casebook: a patient–focused approach. 2nd ed. Stamford, CT: Appleton & Lange, 2000:xvii.
5. Schwinghammer TL. Introduction: how to use this casebook. In: Schwinghammer TL, ed. Pharmacotherapy casebook: A patient–focused approach. 2nd ed. Stamford, CT: Appleton & Lange, 2000:1–6.
6. Schwinghammer TL. Rheumatoid arthritis, Cases 33 and 34. In: Ginsburg D, ed. ASHP’s PharmPrep: Case-Based Board Review, 1st ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2001: 108–11, 112–6

BOOK CHAPTERS: (continued)

7. Schwinghammer TL. Osteoarthritis, Cases 35 and 36. In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 1st ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2001: 117–21, 123–6.
8. Schwinghammer TL. Gout, Cases 37 and 38. In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 1st ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2001: 127–31, 132–6.
9. Schwinghammer TL. Systemic lupus erythematosus, Cases 39 and 40. In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 1st ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2001: 137–40, 141–5.
10. Schwinghammer TL. Introduction: how to use this casebook. In: Schwinghammer TL, ed. Pharmacotherapy casebook: A patient–focused approach. 5th ed. New York, NY: McGraw-Hill, 2002: 1–7.
11. Lamsam GD, Schwinghammer TL. Care planning: A component of the patient care process. In: Schwinghammer TL, ed. Pharmacotherapy casebook: a patient–focused approach. 5th ed. New York: McGraw-Hill, 2002: 25–32.
12. Schwinghammer TL, Lamsam GD. Pharmaceutical care. In: DiPiro JT, ed. Encyclopedia of Clinical Pharmacy. Lincoln Park, NJ: Marcel-Dekker, 2002; 692-7. Available online at www.dekker.com.
13. Schwinghammer TL. Gout, Cases 50 and 51 (on CD-ROM). In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004.
14. Schwinghammer TL. Osteoarthritis, Cases 52 and 53 (on CD-ROM). In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004.
15. Schwinghammer TL. Rheumatoid arthritis, Cases 54 and 55 (on CD-ROM). In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004.
16. Schwinghammer TL. Systemic lupus erythematosus, Cases 56 and 57 (on CD-ROM). In: Ginsburg D, ed. ASHP's PharmPrep: Case-Based Board Review, 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004.
17. Schwinghammer TL. Rheumatic diseases. In: Lee M, ed. Interpreting Laboratory Data, 3rd ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2004:563–92.
18. Schwinghammer TL. Introduction: how to use this casebook. In: Schwinghammer TL, ed. Pharmacotherapy casebook: A patient–focused approach. 6th ed. New York, NY: McGraw-Hill, 2005; 1–7.
19. Lamsam GD, Schwinghammer TL. Care planning: A component of the patient care process. In: Schwinghammer TL, ed. Pharmacotherapy casebook: a patient–focused approach. 6th ed. New York: McGraw-Hill, 2005; 25–32.

BOOK CHAPTERS: (continued)

20. Schwinghammer TL. Introduction: how to use this casebook. In: Schwinghammer TL, Koehler JM, eds. *Pharmacotherapy casebook: A patient-focused approach*. 7th ed. New York, NY: McGraw-Hill, 2008; 1–6.
21. Schwinghammer TL. Care planning: A component of the patient care process. In: Schwinghammer TL, Koehler JM, eds. *Pharmacotherapy casebook: a patient-focused approach*. 7th ed. New York: McGraw-Hill, 2008; 21–28.
22. Schwinghammer TL. Rheumatic diseases. In: Lee M, ed. *Basic Skills in Interpreting Laboratory Data*, 4th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2009.

LETTERS AND EDITORIALS:

1. Schwinghammer TL, Pici M, Pollock S. More on cisplatin storage. Hosp Pharm. 1980; 15:158. Medication error reports. Letter.
2. Kroboth PD, Schwinghammer TL. Hepatotoxicity and erythromycin. Drug Intell Clin Pharm. 1980; 14:627–8. Letter.
3. Schwinghammer TL. Case 7–1981: Mitral valve prolapse—a correction. N Engl J Med. 1981; 304:1364. Letter.
4. Schwinghammer TL, Romano MJ. Comparison of transdermal nitroglycerin products. Am J Hosp Pharm. 1982; 39:1145–6. Letter.
5. Schwinghammer TL, Romano MJ, Wing EJ. Aminoglycoside nephrotoxicity and renal function status. Am J Hosp Pharm. 1986; 43:66–8. Letter.
6. Schwinghammer TL, Reilly M, Rosenfeld C. Cracking of ABS plastic devices used to infuse undiluted etoposide injection. Am J Hosp Pharm. 1988; 45:1277. Letter.
7. Schwinghammer TL, Gentile CJ, Romano MJ. DUE should be multidisciplinary. Am Pharm. 1990; NS30:67. Letter.
8. Schwinghammer TL. Safety, pharmacokinetics, and pharmacodynamics of high-dose etoposide. J Clin Oncol. 1994; 12:2768. Letter.
9. Schwinghammer TL. A case in point. Am J Health-Syst Pharm. 1997; 54:2404-5.
10. Schwinghammer TL. Defining the generalist pharmacy practitioner. Am J Pharm Educ 2004;68(3):Article 76. Viewpoint. Available online at www.ajpe.org.
11. Draugalis JR, DiPiro JT, Zeolla MM, Schwinghammer TL. A career in academic pharmacy: Opportunities, challenges, and rewards. Am J Pharm Educ 2006; 70(1): Article 17: 1–15.

ABBREVIATED NEW DRUG APPLICATION (ANDA) AND OTHER REPORTS:

1. Dittert LW, Schwinghammer TL, Juhl RP, Kroboth FJ. Bioavailability of promethazine suppositories. G & W Laboratories, Inc., South Plainfield, NJ; 1982.

ABBREVIATED NEW DRUG APPLICATION (ANDA) AND OTHER REPORTS: (continued)

2. Dittert LW, Schwinghammer TL, Juhl RP, Kroboth FJ. Intramuscular versus rectal and oral administration of promethazine 50 mg. G & W Laboratories, Inc., South Plainfield, NJ; 1982.
3. Schwinghammer TL, Dittert LW, Wald A, Alvin JD. Bioequivalence study of indomethacin rectal suppositories. G & W Laboratories, Inc., South Plainfield, NJ; February, 1988.
4. Schwinghammer TL, Dittert LW, Wald A, Alvin JD. Bioequivalence study of acetaminophen rectal suppositories. G & W Laboratories, Inc., South Plainfield, NJ; February, 1989.
5. Schwinghammer TL, Dittert LW, Heywood T, Wald A. Pharmacokinetic study of ibuprofen 500 mg rectal suppositories versus 400 mg and 500 mg oral tablets. G & W Laboratories, Inc., South Plainfield, NJ; June, 1990.
6. Schwinghammer TL, Dittert LW, Kapoor W. Pharmacokinetics of aspirin administered by the nasal route. Safe Aid Products, Inc., Hauppauge, NY; July, 1990.
7. Kroboth PD, McAuley JW, Folan M, Schwinghammer TL, Kroboth FJ. An evaluation of the rate and extent of absorption on triazolam pharmacodynamics. The Upjohn Company, Kalamazoo, MI; August, 1990.
8. Schwinghammer TL, Alvin JD, Dittert LW, Minnigh MB, Heywood TJ, Wald A. Bioequivalence study of indomethacin rectal suppositories 50 mg. G & W Laboratories, Inc., South Plainfield, NJ; August, 1991.

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS:

1. Schwinghammer TL. The physical examination: videotaped instruction for pharmacy students. The Annual Meeting of the American Association of Colleges of Pharmacy. Boston, MA; July 23, 1980.
2. Britton HL, Romano MJ, Schwinghammer TL. A successful cephalosporin cost containment program at Montefiore Hospital (P-151). The 15th Annual ASHP Midyear Clinical Meeting. San Francisco, CA; December 9, 1980. Also presented to PSHP Second Annual Midwinter Conference. Pittsburgh, PA; February 20, 1981. Published: ASHP Midyear Clinical Meeting Abstracts. 1980; 15:29.
3. Pici M, Schwinghammer TL. The educational value of the oral contraceptive patient package insert (P-56). The 15th Annual ASHP Midyear Clinical Meeting. San Francisco, CA; December 8, 1980. Published: ASHP Midyear Clinical Meeting Abstracts. 1980; 15:22.
4. Fraley DS, Britton HL, Schwinghammer T, Kalla R. Effect of cimetidine-induced pH changes on the absorption of oral digoxin (P-345). The 16th Annual ASHP Midyear Clinical Meeting. New Orleans, LA; December 10, 1981. Published: ASHP Midyear Clinical Meeting Abstracts. 1981; 16:121.
5. Schwinghammer TL, Romano MJ, Wing EJ. Aminoglycoside audit: cost effectiveness of using gentamicin instead of tobramycin (P-27). The 19th Annual ASHP Midyear Clinical Meeting. Dallas, TX; December 3, 1984. Also presented to the PSHP Midwinter Conference VI. Pittsburgh, PA; March 8, 1985. Published: ASHP Midyear Clinical Meeting Abstracts. 1984; 19:72.

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS: (continued)

6. Schwinghammer TL, Romano MJ, Gilliland BF. Effectiveness of usage guidelines and an antibiotic data form in limiting third-generation cephalosporin use (P-313). The 19th Annual ASHP Midyear Clinical Meeting. Dallas, TX; December 6, 1984. Also presented to the PSHP Midwinter Conference VI. Pittsburgh, PA, March 8, 1985. Published: ASHP Midyear Clinical Meeting Abstracts. 1984; 19:143.
7. Schwinghammer TL, Kubacka RT, Johnston JM, Antal EJ. The pharmacokinetics/pharmacodynamics of glyburide in young and elderly normal volunteers. The 2nd National Meeting of the American Association of Pharmaceutical Scientists. Boston, MA; June 11, 1987. Published: Pharmaceutical Res. 1987; 4 (Suppl.):S-100.
8. Schwinghammer TL, Wang CP, Burckart GJ, Venkataramanan R, Rosenfeld CS, Mangan KF, Shadduck RK. Cyclosporine metabolite profiles in bone marrow transplant patients. The 8th Annual Meeting of the American College of Clinical Pharmacy. Austin, TX; July 22, 1987. Published: Drug Intell Clin Pharm. 1987; 21:20A.
9. Schwinghammer TL. Pharmacokinetics and pharmacodynamics of high-dose etoposide in conjunction with autologous bone marrow transplantation. The American Cancer Society Institutional Research Grant Annual Symposium. Pittsburgh, PA; October 15, 1987.
10. Wang C, Burckart G, Ptachcinski R, Venkataramanan R, Schwinghammer T, Hakala T, Griffith B, Hardesty R, Shadduck R, Starzl T. Cyclosporine metabolite concentrations in blood in renal, liver, heart, and bone marrow transplant patients. Published: Proceedings of the Second International Congress on Cyclosporine. 1987 November 4-7; Washington, DC:234.
11. Romano MJ, Schwinghammer TL, Gilliland BF. Use review of ranitidine injection (P-144E). The 22nd Annual ASHP Midyear Clinical Meeting. Atlanta, GA; December 8, 1987. Published: ASHP Midyear Clinical Meeting Abstracts. 1987; 22:66.
12. Schwinghammer TL, Romano MJ, Gilliland BF, Gentile C. Use review of injectable metoclopramide (P-206E). The 22nd Annual ASHP Midyear Clinical Meeting. Atlanta, GA; December 9, 1987. Published: ASHP Midyear Clinical Meeting Abstracts. 1987; 22:80.
13. Rosenfeld CS, Schwinghammer T, Przepiorka D, Shadduck RK. A phase II study of high-dose busulfan (BU) and VP-16 as a preparative regimen for autologous bone marrow transplantation (ABMT) for lymphoma. The 30th Annual Meeting of the American Society of Hematology. San Antonio, TX; December 3-6, 1988. Published: Blood. 1988; 72 (Suppl 1):404A.
14. Schwinghammer T, Przepiorka D, Venkataramanan R, Burckart G, Ptachcinski R, Rosenfeld C, Shadduck RK. Evaluation of time-dependent cyclosporine (CY) pharmacokinetics (PK) in bone marrow transplant (BMT) recipients. The 30th Annual Meeting of the American Society of Hematology. San Antonio, TX; December 3-6, 1988. Published: Blood. 1988; 72 (Suppl 1):407A.
15. Schwinghammer TL, Romano MJ, Gilliland BF, Gentile C. Use review of intravenous aminophylline (P-122E). The 23rd Annual ASHP Midyear Clinical Meeting. Dallas, TX; December 6, 1988. Also presented to the PSHP Midyear Conference X. Pittsburgh, PA; March 2-3, 1989. Published: ASHP Midyear Clinical Meeting Abstracts. 1988; 23:139.

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS: (continued)

16. Schwinghammer TL, Przepiorka D, Wang CP, Venkataramanan R, Burckart GJ, Rosenfeld CS, Shadduck RK. Cyclosporine (CSA) and metabolite profiles in marrow transplant recipients. The 31st Annual Meeting of the American Society of Hematology. Atlanta, GA; December 2–5, 1989. Published: Blood. 1989; 74(Suppl 1):422a.
17. Schwinghammer TL, Rosenfeld CS, Venkataramanan R, Burckart GJ, Brady J, Jacobs SA, Przepiorka D, Shadduck RK. Relationship between plasma etoposide concentration and myelotoxicity in marrow transplant recipients. The 31st Annual Meeting of the American Society of Hematology. Atlanta, GA; December 2–5, 1989. Published: Blood. 1989; 74(Suppl 1):422a. Also given as an Encore Presentation at the 11th Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA; August 8, 1990. Published: Pharmacotherapy. 1990; 10:243.
18. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Venkataramanan R, Shadduck RK. Variable-dose cyclosporine (CSA) and methylprednisolone (MP) for the prevention of graft-vs-host disease. The 31st Annual Meeting of the American Society of Hematology. Atlanta, GA; December 2–5, 1989. Published: Blood. 1989; 74(Suppl 1):421a.
19. Schwinghammer TL, Mabon BL, Romano MJ, Gilliland BF, Norden CW. Drug use evaluation of aztreonam (P-403E). The 24th Annual ASHP Midyear Clinical Meeting. Atlanta, GA; December 7, 1989. Published: ASHP Midyear Clinical Meeting Abstracts. 1989; 24:128.
20. Gilliland BF, Milan S, Romano MJ, Schwinghammer TL. Effectiveness of a pharmacy and nursing task force (P-116D). The 47th ASHP Annual Meeting. Boston, MA; June 6, 1990. Published: ASHP Annual Meeting Program. 1990; 47:236.
21. Kroboth PD, Schwinghammer TL, Howrie DL, Slatkin DJ, Juhl RP. Educating clinical scientists: experience with a Ph.D. program. The Annual Meeting of the American Association of Colleges of Pharmacy. Salt Lake City, UT; July 10, 1990. Published: Am J Pharm Educ. 1991;55(Suppl):137S.
22. Schwinghammer TL, Kroboth PD, Bergstrom RF, Callaghan JT. The effect of study conditions on the pharmacodynamics of nizatidine. The 11th Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA; August 6, 1990. Published: Pharmacotherapy. 1990; 10:236.
23. Przepiorka D, Schwinghammer TL, Venkataramanan R. Optimizing cyclosporine dosing in marrow transplant recipients. The 19th Annual Meeting of the International Society for Experimental Hematology. Seattle, WA; August 26–30, 1990. Published: Exp Hematol. 1990; 18:684.
24. Shadduck RK, Waheed A, Evans C, Sulecki M, Rosenfeld CS, Schwinghammer TL. Serum and urinary levels of recombinant human granulocyte-macrophage colony-stimulating factor: assessment after intravenous infusion and subcutaneous injection. The 19th Annual Meeting of the International Society for Experimental Hematology. Seattle, WA, August 26–30, 1990. Published: Exp Hematol. 1990; 18:601.
25. Schwinghammer TL, Rosenfeld CS, Bloom EJ, Shadduck RK. Prevention of grades III and IV acute GVHD by adjusted-dose cyclosporine and corticosteroids. The 32nd Annual Meeting of the American Society of Hematology. Boston, MA; November 30–December 4, 1990. Published: Blood. 1990; 76(10)Suppl 1:564a.

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS: (continued)

26. Schwinghammer TL, Shadduck RK, Waheed A, Evans C, Sulecki M, Rosenfeld CS. Pharmacokinetics of recombinant human granulocyte–macrophage colony–stimulating factor (GM–CSF) after intravenous infusion and subcutaneous injection. The American College of Clinical Pharmacy 1991 Winter Practice and Research Forum. Fort Lauderdale, FL; February 11, 1991. Published: Pharmacotherapy. 1991; 11(1):105.
27. Gilliland BF, Schwinghammer TL, Romano MJ. Analysis of pharmacists' interventions after review of medication orders (P–330E). The 25th Annual ASHP Midyear Clinical Meeting. Las Vegas, NV; December 5, 1990. Also presented to the PSHP Midyear Conference. Pittsburgh, PA; March 21–22, 1991. Published: ASHP Midyear Clinical Meeting Abstracts. 1990; 25:119.
28. Schwinghammer TL, Fleming RA, Rosenfeld CS, Shadduck RK, Stewart CF. Pharmacokinetics and protein binding of high–dose etoposide. The 92nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. San Antonio, TX; March 15, 1991. Published: Clin Pharmacol Ther. 1991; 49:195. Also given as an Encore Presentation at the 12th Annual Meeting of the American College of Clinical Pharmacy. Minneapolis, MN; August 21, 1991. Published: Pharmacotherapy. 1991; 11:282.
29. Gilliland BF, Stanislav GH, Constantin JJ, Schwinghammer TL. Analysis of returned medications: the lost step in the medication–use process (P–79D). The 48th ASHP Annual Meeting. San Diego, CA; June 4, 1991. Published: ASHP Annual Meeting Program. 1991; 48:92.
30. Gilliland BF, Schwinghammer TL, Hirsh JD. Multi–institutional drug use evaluation of triazolam dosing and adverse effects (P–591E). The 26th Annual ASHP Midyear Clinical Meeting. New Orleans, LA; December 12, 1991. Published: ASHP Midyear Clinical Meeting Abstracts. 1991; 26:233.
31. Matzke GR, Comstock TJ, Frye RF, Gillikin S, Rault RM, Schwinghammer TL, Kirschbaum B. The pharmacokinetics of epoetin alfa (EPO) are nonlinear following low dose administration. The 25th Annual Meeting of the American Society of Nephrology. Baltimore, MD, November 15–18, 1992. Published: J Am Soc Nephrol. 1992; 3(3):428.
32. Schwinghammer TL, Bloom EJ. Prevention of chronic graft–versus–host disease (CGVHD) with corticosteroids and an extended regimen of cyclosporine (CSA). The 34th Annual Meeting of the American Society of Hematology. Anaheim, CA, December 6, 1992. Published: Blood. 1992; 80(Suppl 1);133a. Also given as an Encore Presentation at the 14th Annual Meeting of the American College of Clinical Pharmacy. Reno, NV; August 18, 1993. Published: Pharmacotherapy. 1993; 13:296.
33. Levin WA, Schwinghammer TL. Efficacy and toxicity of cyclosporine plus corticosteroids for prevention of acute and chronic graft–versus–host disease. The 16th Annual Undergraduate Research Seminar. Morgantown, WV; October 17, 1994.
34. Schwinghammer TL, Kroboth PD, Szajna JM, Dudjak LA, Brown FH. Documentation of interventions on a multidisciplinary health care team. The 29th Annual ASHP Midyear Clinical Meeting. Miami Beach, FL; December 8, 1994. Published: Int Pharm Abstracts. 1994;31:2209.

ABSTRACTS AND SCIENTIFIC PRESENTATIONS AT MEETINGS: (continued)

35. Stoehr GP, Schwinghammer TL, Piantanida, M. Student Learning Portfolios: Liberty or Tyranny? The 96th Annual Meeting of the American Association of Colleges of Pharmacy. Philadelphia, PA, July 11, 1995. Published: Am J Pharm Educ. 1995; 59(Winter Suppl): 101S.
36. Rybka WB, Bloom E, Donnenberg AD, Lister J, Pincus S, Schwinghammer T, de Magalhaes–Silverman M, Ball E. Treatment outcomes for the management of graft–vs–host disease following cyclosporine and prednisone prophylaxis. The 37th Annual Meeting of the American Society of Hematology. Seattle, WA, December 1–5,1995. Published: Blood. 1995; 86(Suppl 1):395a.
37. Piantanida M, Schwinghammer T, Stoehr G. Taking stock: a heuristic model for assessing the status of curricular reform. The 97th Annual Meeting of the American Association of Colleges of Pharmacy. Reno, NV, July 14–18, 1996. Published: Am J Pharm Educ. 1996; 60(Winter Suppl):107S.
37. Berringer R, Somma M, Szymczak M, Schwartz H, Drew G, Schwinghammer T, Smith R, Mastrian J, Kroboth P. A standardized medication therapy management service in a community pharmacy chain. The 2005 American Pharmacists Association Annual Meeting. Orlando, FL, April 1–5, 2005. Published: JAPhA 2005;45(2): 229–230.
38. Somma M, Berringer R, Kroboth P, Smith R, Schwinghammer T. Enhancing the pharmacist’s role through community partnerships: TRIO. The 2005 American Pharmacists Association Annual Meeting. Orlando, FL, April 1–5, 2005. Published: JAPhA 2005;45(2): 233–234.
39. Abate MA, See CJ, Stamatakis MK, Schwinghammer TL, Stout P, Szklarz GD, Scott V. Developing and mapping school educational outcomes (EOs) as the foundation for a comprehensive assessment plan. The American Association of Colleges of Pharmacy Annual Meeting, Orlando, FL, July 14–17, 2007. Published: Am J Pharm Educ 2007;72 (3): Article 60, page 72.
40. Elliott DP, Stamatakis MK, Schwinghammer TL, Brister C. Accountability for learning: whose job is it? The American Association of Colleges of Pharmacy Annual meeting, Chicago, IL, July 20–23, 2008. Published: Am J Pharm Educ 2008;72 (3):Article 72, page 32.

RESEARCH GRANTS AND AWARDS

1. Schwinghammer TL. The physical examination: videotaped instruction for pharmacy students. \$175, Office of Faculty Development, University of Pittsburgh, Pittsburgh, PA, 1979.
2. Fraley D, Britton HL, Schwinghammer TL, Kalla R. Effect of cimetidine–induced pH changes on the absorption of oral digoxin. \$3,000, Smith Kline & French Laboratories, Philadelphia, PA, 1979–1980.
3. Dittert LW, Schwinghammer TL, Juhl RP, Kroboth FJ. Bioavailability of promethazine suppositories. \$30,000, G & W Laboratories Incorporated, South Plainfield, NJ, 1981–1982.
4. Dittert LW, Schwinghammer TL, Juhl RP, Kroboth FJ. Comparison of the bioavailability of intramuscular promethazine injection with rectal administration. \$2,500, G & W Laboratories Incorporated, South Plainfield, NJ, 1981–1982.

RESEARCH GRANTS AND AWARDS: (continued)

5. Schwinghammer TL. Pharmacokinetics and drug interactions of cyclosporine in dogs. \$3,923, Research Development Fund, University of Pittsburgh, Pittsburgh, PA, 1983.
6. Schwinghammer TL, Juhl RP, Johnston J. Single-dose pharmacokinetics and pharmacodynamics of glyburide in the elderly. \$12,000, The Upjohn Company, Kalamazoo, MI, 1985–1986.
7. Schwinghammer TL, Dittert LW, Alvin JD, Wald A. Bioequivalence study of indomethacin rectal suppositories. \$35,000, G & W Laboratories Incorporated, South Plainfield, NJ, 1986.
8. Kroboth PD, Schwinghammer TL. Pharmacodynamic analysis of nizatidine (LY139037) data. \$13,200, Eli Lilly and Company, Indianapolis, IN, 1986–1987.
9. Schwinghammer TL, Rosenfeld CS. Pharmacokinetics and pharmacodynamics of high-dose etoposide in patients with small cell lung cancer. \$6,785, American Cancer Society Institutional Research Grant, 1986–1987.
10. Norden CW, Schwinghammer TL. Pharmacokinetics of cephadrine in young and elderly normal volunteers. \$5,000, Smith Kline & French Laboratories, Philadelphia, PA, 1987.
11. Schwinghammer TL, Dittert LW, Alvin JD, Wald A. Bioequivalence study of acetaminophen rectal suppositories. \$17,000, G & W Laboratories Incorporated, South Plainfield, NJ, 1988.
12. Schwinghammer TL. Pharmacokinetics and pharmacodynamics of high-dose etoposide in conjunction with bone marrow transplantation. \$14,850, Bristol-Myers U.S. Pharmaceutical Group, Evansville, IN, 1988–1989.
13. Schwinghammer TL, Dittert LW, Winters SJ. Bioequivalence of bromocriptine tablets: pilot studies. \$10,585, Serono Laboratories, Inc., 1988–1989.
14. Schwinghammer TL, Dittert LW, Kapoor W. Pharmacokinetics of aspirin administered by the nasal route. \$6,000, Safe-Aid Products, Inc., 1989.
15. Schwinghammer TL, Dittert LW, Wald A. Bioequivalence of promethazine rectal suppositories: pilot studies. \$15,734, G & W Laboratories, Incorporated, South Plainfield, NJ, 1989–1990.
16. Schwinghammer TL, Dittert LW, Wald A. Comparison of the bioavailability of ibuprofen 500 mg rectal suppositories with 400 mg and 500 mg oral doses in healthy volunteers. \$11,415, G & W Laboratories, Incorporated, South Plainfield, NJ, 1990.
17. Schwinghammer TL, Dittert LW, Wald A. A two-way crossover bioavailability study of promethazine 25 mg rectal suppositories in healthy male volunteers. \$14,582, G & W Laboratories, Incorporated, South Plainfield, NJ, 1990.
18. Kroboth, PD, Schwinghammer TL, McAuley JW, Kroboth FJ, Folan MM. An evaluation of the influence of rate and extent of absorption on triazolam pharmacodynamics. \$62,700, The Upjohn Company, Kalamazoo, MI, 1990.
19. Schwinghammer TL, Dittert LW, Alvin JD, Wald A. Bioequivalence study of indomethacin rectal suppositories. \$18,000, G & W Laboratories, Incorporated, South Plainfield, NJ, 1991.

20. Schwinghammer TL. Influence of dosage regimen on cyclosporine efficacy and adverse effects after allogeneic marrow transplantation. \$3,000, University of Pittsburgh Pharmacy Associates, Pittsburgh, PA. 1994.